Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Multicenter Open Label Phase 2 Single Arm Study of Ixazomib, Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma Characterized With Genomic Abnormalities of Adverse Adverse Prognostic

NCT03683277 is registered in ClinicalTrials.gov with Intergroupe Francophone du Myelome as lead sponsor.

NCT NCT03683277
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03683277 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Multicenter Open Label Phase 2 Single Arm Study of Ixazomib, Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma Characterized With Genomic Abnormalities of Adverse Adverse Prognostic
Lead sponsor
Intergroupe Francophone du Myelome
Phase
Phase 2
Overall status
Terminated
Start date
November 3, 2019
Completion date
February 10, 2023
Enrollment
26 (actual)
Sites
28

Conditions

As the registry lists them; a condition with its own page is linked.

genetic condition, multiple myeloma, relapsed and refractory multiple myeloma